Understanding the role of ETS-mediated gene regulation in complex biological processes

Advances in Cancer Research

Volumn 119, Issue , 2013, Pages 1-61

  Findlay, Victoria J ^a   LaRue, Amanda C ^a,b   Turner, David P ^a   Watson, Patricia M ^a   Watson, Dennis K ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

Cancer; ETS; Regulation; Target genes; Transcription factors

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN; CYCLIN D1; GAMBOGIC ACID; LUTEOLIN; MATRIX METALLOPROTEINASE; MICRORNA; MONOCYTE CHEMOTACTIC PROTEIN 1; NANOPARTICLE; PROSTATE SPECIFIC ANTIGEN; TRANSCRIPTION FACTOR ETS; VASCULOTROPIN; ETS1 PROTEIN, HUMAN; ONCOPROTEIN; TRANSCRIPTION FACTOR ETS 1;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER RECURRENCE; CELL DIFFERENTIATION; CELL DIVISION; CHROMOSOME TRANSLOCATION; COLORECTAL CANCER; DNA BINDING; DRUG DELIVERY SYSTEM; ENDOTHELIUM CELL; EWING SARCOMA; GENE ACTIVATION; GENE CONTROL; GENE CONVERSION; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE MUTATION; GENE TARGETING; GENETIC MODEL; GENOME ANALYSIS; HUMAN; JACOBSEN SYNDROME; KNOCKOUT GENE; LEUKEMIA; METASTASIS; METASTASIS INHIBITION; MINIMAL RESIDUAL DISEASE; MOLECULAR BIOLOGY; MULTIGENE FAMILY; NEOPLASM; NONHUMAN; PANCREAS CANCER; PHENOTYPE; PLEIOTROPY; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; RNA INTERFERENCE; SCLERODERMA; SPLEEN FOCUS FORMING VIRUS; STOMACH CANCER; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TRANSCRIPTION INITIATION; TUMOR MICROENVIRONMENT; ANIMAL; CHEMISTRY; DISEASE COURSE; GENE EXPRESSION REGULATION; GENETICS; HOMEOSTASIS; METABOLISM; MOUSE; PATHOLOGY; PHYSIOLOGY; PROTEIN ANALYSIS; RECURRENT DISEASE; TRANSGENIC MOUSE;

ANIMALS; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEOSTASIS; HUMANS; MICE; MICE, TRANSGENIC; MICRORNAS; MULTIGENE FAMILY; NEOPLASM METASTASIS; NEOPLASMS; ONCOGENE PROTEINS, FUSION; PHENOTYPE; PROMOTER REGIONS, GENETIC; PROTEIN INTERACTION MAPPING; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEIN C-ETS-1; RECURRENCE;

EID: 84893515646     PISSN: 0065230X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-407190-2.00001-0     Document Type: Chapter

References (257)

1. Artlett C.M. Animal models of scleroderma: Fresh insights. Current Opinion in Rheumatology 2010, 22:677-682.
2. Arvand A., Denny C.T. Biology of EWS/ETS fusions in Ewing's family tumors. Oncogene 2001, 20:5747-5754.
3. Asano Y., Bujor A.M., Trojanowska M. The impact of Fli1 deficiency on the pathogenesis of systemic sclerosis. Journal of Dermatological Science 2010, 59:153-162.
4. Asano Y., Czuwara J., Trojanowska M. Transforming growth factor-beta regulates DNA binding activity of transcription factor Fli1 by p300/CREB-binding protein-associated factor-dependent acetylation. Journal of Biological Chemistry 2007, 282:34672-34683.
5. Asano Y., Markiewicz M., Kubo M., Szalai G., Watson D.K., Trojanowska M. Transcription factor Fli1 regulates collagen fibrillogenesis in mouse skin. Molecular and Cellular Biology 2009, 29:425-434.
6. Asano Y., Stawski L., Hant F., Highland K., Silver R., Szalai G., et al. Endothelial Fli1 deficiency impairs vascular homeostasis: A role in scleroderma vasculopathy. The American Journal of Pathology 2010, 176:1983-1998.
7. Asano Y., Trojanowska M. Phosphorylation of Fli1 at threonine 312 by protein kinase C delta promotes its interaction with p300/CREB-binding protein-associated factor and subsequent acetylation in response to transforming growth factor beta. Molecular and Cellular Biology 2009, 29:1882-1894.
8. Ayadi A., Zheng H., Sobieszczuk P., Buchwalter G., Moerman P., Alitalo K., et al. Net-targeted mutant mice develop a vascular phenotype and up-regulate egr-1. EMBO Journal 2001, 20:5139-5152.
9. Baillat D., Begue A., Stehelin D., Aumercier M. ETS-1 transcription factor binds cooperatively to the palindromic head to head ETS-binding sites of the stromelysin-1 promoter by counteracting autoinhibition. Journal of Biological Chemistry 2002, 277:29386-29398.
10. Ban J., Jug G., Mestdagh P., Schwentner R., Kauer M., Aryee D.N., et al. Hsa-mir-145 is the top EWS-FLI1-repressed microRNA involved in a positive feedback loop in Ewing's sarcoma. Oncogene 2011, 30:2173-2180.
11. Barber-Rotenberg J.S., Selvanathan S.P., Kong Y., Erkizan H.V., Snyder T.M., Hong S.P., et al. Single enantiomer of YK-4-279 demonstrates specificity in targeting the oncogene EWS-FLI1. Oncotarget 2012, 3:172-182.
12. Batliner J., Buehrer E., Federzoni E.A., Jenal M., Tobler A., Torbett B.E., et al. Transcriptional regulation of MIR29B by PU.1 (SPI1) and MYC during neutrophil differentiation of acute promyelocytic leukaemia cells. British Journal of Haematology 2012, 157:270-274.
13. Behrens P., Mathiak M., Mangold E., Kirdorf S., Wellmann A., Fogt F., et al. Stromal expression of invasion-promoting, matrix-degrading proteases MMP-1 and -9 and the Ets 1 transcription factor in HNPCC carcinomas and sporadic colorectal cancers. International Journal of Cancer 2003, 107:183-188.
14. Behrens P., Rothe M., Florin A., Wellmann A., Wernert N. Invasive properties of serous human epithelial ovarian tumors are related to Ets-1, MMP-1 and MMP-9 expression. International Journal of Molecular Medicine 2001, 8:149-154.
15. Behrens P., Rothe M., Wellmann A., Krischler J., Wernert N. The Ets-1 transcription factor is up-regulated together with MMP 1 and MMP 9 in the stroma of pre-invasive breast cancer. The Journal of Pathology 2001, 194:43-50.
16. Benbow U., Tower G.B., Wyatt C.A., Buttice G., Brinckerhoff C.E. High levels of MMP-1 expression in the absence of the 2G single nucleotide polymorphism is mediated by p38 and ERK1/2 mitogen-activated protein kinases in VMM5 melanoma cells. Journal of Cellular Biochemistry 2002, 86:307-319.
17. Benz C.C., O'Hagan R.C., Richter B., Scott G.K., Chang C.H., Xiong X., et al. HER2/Neu and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancer. Oncogene 1997, 15:1513-1525.
18. Blair D.G., Athanasiou M. Ets and retroviruses-Transduction and activation of members of the Ets oncogene family in viral oncogenesis. Oncogene 2000, 19:6472-6481.
19. Bosc D.G., Goueli B.S., Janknecht R. HER2/Neu-mediated activation of the ETS transcription factor ER81 and its target gene MMP-1. Oncogene 2001, 20:6215-6224.
20. Bronisz A., Godlewski J., Wallace J.A., Merchant A.S., Nowicki M.O., Mathsyaraja H., et al. Reprogramming of the tumour microenvironment by stromal PTEN-regulated miR-320. Nature Cell Biology 2012, 14:159-167.
21. Buchwalter G., Gross C., Wasylyk B. Ets ternary complex transcription factors. Gene 2004, 324:1-14.
22. Buggy Y., Maguire T.M., McDermott E., Hill A.D., O'Higgins N., Duffy M.J. Ets2 transcription factor in normal and neoplastic human breast tissue. European Journal of Cancer 2006, 42:485-491.
23. Buggy Y., Maguire T.M., McGreal G., McDermott E., Hill A.D., O'Higgins N., et al. Overexpression of the Ets-1 transcription factor in human breast cancer. British Journal of Cancer 2004, 91:1308-1315.
24. Bui T.V., Mendell J.T. Myc: Maestro of microRNAs. Genes & Cancer 2010, 1:568-575.
25. Carbone G.M., McGuffie E.M., Collier A., Catapano C.V. Selective inhibition of transcription of the Ets2 gene in prostate cancer cells by a triplex-forming oligonucleotide. Nucleic Acids Research 2003, 31:833-843.
26. Carbone G.M., Napoli S., Valentini A., Cavalli F., Watson D.K., Catapano C.V. Triplex DNA-mediated downregulation of Ets2 expression results in growth inhibition and apoptosis in human prostate cancer cells. Nucleic Acids Research 2004, 32:4358-4367.
27. Cesari F., Brecht S., Vintersten K., Vuong L.G., Hofmann M., Klingel K., et al. Mice deficient for the ets transcription factor elk-1 show normal immune responses and mildly impaired neuronal gene activation. Molecular and Cellular Biology 2004, 24:294-305.
28. Chakrabarti R., Hwang J., Andres Blanco M., Wei Y., Lukacisin M., Romano R.A., et al. Elf5 inhibits the epithelial-mesenchymal transition in mammary gland development and breast cancer metastasis by transcriptionally repressing Snail2. Nature Cell Biology 2012, 14:1212-1222.
29. Chakrabarti S.R., Nucifora G. The leukemia-associated gene TEL encodes a transcription repressor which associates with SMRT and mSin3A. Biochemical and Biophysical Research Communications 1999, 264:871-877.
30. Chakrabarti S.R., Sood R., Ganguly S., Bohlander S., Shen Z., Nucifora G. Modulation of TEL transcription activity by interaction with the ubiquitin-conjugating enzyme UBC9. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:7467-7472.
31. Chakrabarti R., Wei Y., Romano R.A., DeCoste C., Kang Y., Sinha S. Elf5 regulates mammary gland stem/progenitor cell fate by influencing notch signaling. Stem Cells 2012, 30:1496-1508.
32. Chang C.H., Scott G.K., Kuo W.L., Xiong X., Suzdaltseva Y., Park J.W., et al. ESX: A structurally unique Ets overexpressed early during human breast tumorigenesis. Oncogene 1997, 14:1617-1622.
33. Charlot C., Dubois-Pot H., Serchov T., Tourrette Y., Wasylyk B. A review of post-translational modifications and subcellular localization of Ets transcription factors: Possible connection with cancer and involvement in the hypoxic response. Methods in Molecular Biology 2010, 647:3-30.
34. Chen C., Ouyang W., Grigura V., Zhou Q., Carnes K., Lim H., et al. ERM is required for transcriptional control of the spermatogonial stem cell niche. Nature 2005, 436:1030-1034.
35. Chen K., Rajewsky N. Deep conservation of microRNA-target relationships and 3'UTR motifs in vertebrates, flies, and nematodes. Cold Spring Harbor Symposia on Quantitative Biology 2006, 71:149-156.
36. Choi H.J., Geng Y., Cho H., Li S., Giri P.K., Felio K., et al. Differential requirements for the Ets transcription factor Elf-1 in the development of NKT cells and NK cells. Blood 2011, 117:1880-1887.
37. Chou Y.T., Lin H.H., Lien Y.C., Wang Y.H., Hong C.F., Kao Y.R., et al. EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF. Cancer Research 2010, 70:8822-8831.
38. Christoffersen N.R., Shalgi R., Frankel L.B., Leucci E., Lees M., Klausen M., et al. p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC. Cell Death and Differentiation 2010, 17:236-245.
39. Chun C.Z., Remadevi I., Schupp M.O., Samant G.V., Pramanik K., Wilkinson G.A., et al. Fli+ etsrp+ hemato-vascular progenitor cells proliferate at the lateral plate mesoderm during vasculogenesis in zebrafish. PLoS One 2011, 6:e14732.
40. Ciau-Uitz A., Pinheiro P., Gupta R., Enver T., Patient R. Tel1/ETV6 specifies blood stem cells through the agency of VEGF signaling. Developmental Cell 2010, 18:569-578.
41. Colucci F., Samson S.I., DeKoter R.P., Lantz O., Singh H., Di Santo J.P. Differential requirement for the transcription factor PU.1 in the generation of natural killer cells versus B and T cells. Blood 2001, 97:2625-2632.
42. Coskun E., von der Heide E.K., Schlee C., Kuhnl A., Gokbuget N., Hoelzer D., et al. The role of microRNA-196a and microRNA-196b as ERG regulators in acute myeloid leukemia and acute T-lymphoblastic leukemia. Leukemia Research 2011, 35:208-213.
43. Costello P.S., Nicolas R.H., Watanabe Y., Rosewell I., Treisman R. Ternary complex factor SAP-1 is required for Erk-mediated thymocyte positive selection. Nature Immunology 2004, 5:289-298.
44. Costello P., Nicolas R., Willoughby J., Wasylyk B., Nordheim A., Treisman R. Ternary complex factors SAP-1 and Elk-1, but not net, are functionally equivalent in thymocyte development. Journal of Immunology 2010, 185:1082-1092.
45. Cowden Dahl K.D., Dahl R., Kruichak J.N., Hudson L.G. The epidermal growth factor receptor responsive miR-125a represses mesenchymal morphology in ovarian cancer cells. Neoplasia 2009, 11:1208-1215.
46. Cowden Dahl K.D., Symowicz J., Ning Y., Gutierrez E., Fishman D.A., Adley B.P., et al. Matrix metalloproteinase 9 is a mediator of epidermal growth factor-dependent e-cadherin loss in ovarian carcinoma cells. Cancer Research 2008, 68:4606-4613.
47. Czuwara-Ladykowska J., Sementchenko V.I., Watson D.K., Trojanowska M. Ets1 is an effector of the transforming growth factor Beta (tgf-Beta ) signaling pathway and an antagonist of the profibrotic effects of tgf-Beta. Journal of Biological Chemistry 2002, 277:20399-20408.
48. Czuwara-Ladykowska J., Shirasaki F., Jackers P., Watson D.K., Trojanowska M. Fli-1 inhibits collagen type I production in dermal fibroblasts via an Sp1-dependent pathway. Journal of Biological Chemistry 2001, 276:20839-20848.
49. Darnell J.E. Transcription factors as targets for cancer therapy. Nature Reviews. Cancer 2002, 2:740-749.
50. Delattre O., Zucman J., Plougastel B., Desmaze C., Melot T., Peter M., et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 1992, 359:162-165.
51. de Lau W., Kujala P., Schneeberger K., Middendorp S., Li V.S., Barker N., et al. Peyer's patch M cells derived from Lgr5(+) stem cells require SpiB and are induced by RankL in cultured "miniguts". Molecular and Cellular Biology 2012, 32:3639-3647.
52. De Vito C., Riggi N., Suva M.L., Janiszewska M., Horlbeck J., Baumer K., et al. Let-7a is a direct EWS-FLI-1 target implicated in Ewing's sarcoma development. PLoS One 2011, 6:e23592.
53. Diakos C., Zhong S., Xiao Y., Zhou M., Vasconcelos G.M., Krapf G., et al. TEL-AML1 regulation of survivin and apoptosis via miRNA-494 and miRNA-320a. Blood 2010, 116:4885-4893.
54. DiTacchio L., Bowles J., Shin S., Lim D.S., Koopman P., Janknecht R. Transcription factors ER71/ETV2 and SOX9 participate in a positive feedback loop in fetal and adult mouse testis. Journal of Biological Chemistry 2012, 287:23657-23666.
55. Doane A.S., Danso M., Lal P., Donaton M., Zhang L., Hudis C., et al. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 2006, 25:3994-4008.
56. Dohjima T., Lee N.S., Li H., Ohno T., Rossi J.J. Small interfering RNAs expressed from a Pol III promoter suppress the EWS/Fli-1 transcript in an Ewing sarcoma cell line. Molecular Therapy 2003, 7:811-816.
57. Eichner L.J., Perry M.C., Dufour C.R., Bertos N., Park M., St-Pierre J., et al. miR-378(*) mediates metabolic shift in breast cancer cells via the PGC-1beta/ERRgamma transcriptional pathway. Cell Metabolism 2010, 12:352-361.
58. Elvert G., Kappel A., Heidenreich R., Englmeier U., Lanz S., Acker T., et al. Cooperative interaction of hypoxia-inducible factor-2alpha (HIF-2alpha) and Ets-1 in the transcriptional activation of vascular endothelial growth factor receptor-2 (Flk-1). Journal of Biological Chemistry 2003, 278:7520-7530.
59. Farnham P.J. Insights from genomic profiling of transcription factors. Nature Reviews. Genetics 2009, 10:605-616.
60. Feldman R.J., Sementchenko V.I., Gayed M., Fraig M.M., Watson D.K. Pdef expression in human breast cancer is correlated with invasive potential and altered gene expression. Cancer Research 2003, 63:4626-4631.
61. Feldman R.J., Sementchenko V.I., Watson D.K. The epithelial-specific Ets factors occupy a unique position in defining epithelial proliferation, differentiation and carcinogenesis. Anticancer Research 2003, 23:2125-2131.
62. Feng W., Xing D., Hua P., Zhang Y., Chen Y.F., Oparil S., et al. The transcription factor ETS-1 mediates proinflammatory responses and neointima formation in carotid artery endoluminal vascular injury. Hypertension 2010, 55:1381-1388.
63. Ferdous A., Caprioli A., Iacovino M., Martin C.M., Morris J., Richardson J.A., et al. Nkx2-5 transactivates the Ets-related protein 71 gene and specifies an endothelial/endocardial fate in the developing embryo. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:814-819.
64. Findlay V.J., Turner D.P., Moussa O., Watson D.K. MicroRNA-mediated inhibition of prostate-derived Ets factor messenger RNA translation affects prostate-derived Ets factor regulatory networks in human breast cancer. Cancer Research 2008, 68:8499-8506.
65. Findlay V.J., Turner D.P., Yordy J.S., McCarragher B., Shriver M.R., Szalai G., et al. Prostate-derived ETS factor regulates epithelial-to-mesenchymal transition through both slug-dependent and independent mechanisms. Genes & Cancer 2011, 2:120-129.
66. Fisher R.J., Fivash M., Casas-Finet J., Erickson J.W., Kondoh A., Bladen S.V., et al. Real-time DNA binding measurements of the ETS1 recombinant oncoproteins reveal significant kinetic differences between the p42 and p51 isoforms. Protein Science 1994, 3:257-266.
67. Fitzsimmons D., Lutz R., Wheat W., Chamberlin H.M., Hagman J. Highly conserved amino acids in Pax and Ets proteins are required for DNA binding and ternary complex assembly. Nucleic Acids Research 2001, 29:4154-4165.
68. Flentjar N., Chu P.Y., Ng A.Y., Johnstone C.N., Heath J.K., Ernst M., et al. TGF-betaRII rescues development of small intestinal epithelial cells in Elf3-deficient mice. Gastroenterology 2007, 132:1410-1419.
69. Foulds C.E., Nelson M.L., Blaszczak A.G., Graves B.J. Ras/mitogen-activated protein kinase signaling activates Ets-1 and Ets-2 by CBP/p300 recruitment. Molecular and Cellular Biology 2004, 24:10954-10964.
70. Franzetti G.A., Laud-Duval K., Bellanger D., Stern M.H., Sastre-Garau X., Delattre O. MiR-30a-5p connects EWS-FLI1 and CD99, two major therapeutic targets in Ewing tumor. Oncogene 2012, 10.1038/onc.2012.403.
71. Galang C.K., Muller W.J., Foos G., Oshima R.G., Hauser C.A. Changes in the expression of many Ets family transcription factors and of potential target genes in normal mammary tissue and tumors. Journal of Biological Chemistry 2004, 279:11281-11292.
72. Garrett-Sinha L.A., Su G.H., Rao S., Kabak S., Hao Z., Clark M.R., et al. PU.1 and Spi-B are required for normal B cell receptor-mediated signal transduction. Immunity 1999, 10:399-408.
73. Garvie C.W., Pufall M.A., Graves B.J., Wolberger C. Structural analysis of the autoinhibition of Ets-1 and its role in protein partnerships. Journal of Biological Chemistry 2002, 277:45529-45536.
74. Gavrilov D., Kenzior O., Evans M., Calaluce R., Folk W.R. Expression of urokinase plasminogen activator and receptor in conjunction with the ets family and AP-1 complex transcription factors in high grade prostate cancers. European Journal of Cancer 2001, 37:1033-1040.
75. Georgiou P., Maroulakou I.G., Green J.E., Dantis P., Romano-Spica V., Kottaridis S., et al. Expression of ets family of genes in systemic lupus erythematosus and Sjogren's syndrome. International Journal of Oncology 1996, 9:9-18.
76. Goel A., Janknecht R. Acetylation-mediated transcriptional activation of the ETS protein ER81 by p300, P/CAF, and HER2/Neu. Molecular and Cellular Biology 2003, 23:6243-6254.
77. Golub T.R., Barker G.F., Lovett M., Gilliland D.G. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5; 12) chromosomal translocation. Cell 1994, 77:307-316.
78. Guarino M., Rubino B., Ballabio G. The role of epithelial-mesenchymal transition in cancer pathology. Pathology 2007, 39:305-318.
79. Gutierrez-Hartmann A., Duval D.L., Bradford A.P. ETS transcription factors in endocrine systems. Trends in Endocrinology and Metabolism 2007, 18:150-158.
80. Hahne J.C., Fuchs T., El Mustapha H., Okuducu A.F., Bories J.C., Wernert N. Expression pattern of matrix metalloproteinase and TIMP genes in fibroblasts derived from Ets-1 knock-out mice compared to wild-type mouse fibroblasts. International Journal of Molecular Medicine 2006, 18:153-159.
81. Hahne J.C., Fuchs T., Florin A., Edwards D., Pourtier A., Soncin F., et al. Evaluation of effects caused by differentially spliced Ets-1 transcripts in fibroblasts. International Journal of Oncology 2011, 39:1073-1082.
82. Hahne J.C., Okuducu A.F., Fuchs T., Florin A., Wernert N. Identification of ETS-1 target genes in human fibroblasts. International Journal of Oncology 2011, 38:1645-1652.
83. Hanahan D., Coussens L.M. Accessories to the crime: Functions of cells recruited to the tumor microenvironment. Cancer Cell 2012, 21:309-322.
84. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
85. Hanahan D., Weinberg R.A. Hallmarks of cancer: The next generation. Cell 2011, 144:646-674.
86. Harris T.A., Yamakuchi M., Kondo M., Oettgen P., Lowenstein C.J. Ets-1 and Ets-2 regulate the expression of microRNA-126 in endothelial cells. Arteriosclerosis, Thrombosis, and Vascular Biology 2010, 30:1990-1997.
87. Hart A., Melet F., Grossfeld P., Chien K., Jones C., Tunnacliffe A., et al. Fli-1 is required for murine vascular and megakaryocytic development and is hemizygously deleted in patients with thrombocytopenia. Immunity 2000, 13:167-177.
88. He L., He X., Lowe S.W., Hannon G.J. microRNAs join the p53 network-Another piece in the tumour-suppression puzzle. Nature Reviews. Cancer 2007, 7:819-822.
89. Hendricks T.J., Fyodorov D.V., Wegman L.J., Lelutiu N.B., Pehek E.A., Yamamoto B., et al. Pet-1 ETS gene plays a critical role in 5-HT neuron development and is required for normal anxiety-like and aggressive behavior. Neuron 2003, 37:233-247.
90. Hewett P.W., Daft E.L., Laughton C.A., Ahmad S., Ahmed A., Murray J.C. Selective inhibition of the human tie-1 promoter with triplex-forming oligonucleotides targeted to Ets binding sites. Molecular Medicine 2006, 12:8-16.
91. Hikami K., Kawasaki A., Ito I., Koga M., Ito S., Hayashi T., et al. Association of a functional polymorphism in the 3'-untranslated region of SPI1 with systemic lupus erythematosus. Arthritis and Rheumatism 2011, 63:755-763.
92. Hollenhorst P.C., Chandler K.J., Poulsen R.L., Johnson W.E., Speck N.A., Graves B.J. DNA specificity determinants associate with distinct transcription factor functions. PLoS Genetics 2009, 5:e1000778.
93. Hollenhorst P.C., Ferris M.W., Hull M.A., Chae H., Kim S., Graves B.J. Oncogenic ETS proteins mimic activated RAS/MAPK signaling in prostate cells. Genes & Development 2011, 25:2147-2157.
94. Hollenhorst P.C., Jones D.A., Graves B.J. Expression profiles frame the promoter specificity dilemma of the ETS family of transcription factors. Nucleic Acids Research 2004, 32:5693-5702.
95. Hollenhorst P.C., McIntosh L.P., Graves B.J. Genomic and biochemical insights into the specificity of ETS transcription factors. Annual Review of Biochemistry 2011, 80:437-471.
96. Hollenhorst P.C., Shah A.A., Hopkins C., Graves B.J. Genome-wide analyses reveal properties of redundant and specific promoter occupancy within the ETS gene family. Genes & Development 2007, 21:1882-1894.
97. Horst D., Gu X., Bhasin M., Yang Q., Verzi M., Lin D., et al. Requirement of the epithelium-specific Ets transcription factor Spdef for mucous gland cell function in the gastric antrum. Journal of Biological Chemistry 2010, 285:35047-35055.
98. Hsu T., Trojanowska M., Watson D.K. Ets proteins in biological control and cancer. Journal of Cellular Biochemistry 2004, 91:896-903.
99. Huang S., Van Arsdall M., Tedjarati S., McCarty M., Wu W., Langley R., et al. Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. Journal of the National Cancer Institute 2002, 94:1134-1142.
100. Hu-Lieskovan S., Heidel J.D., Bartlett D.W., Davis M.E., Triche T.J. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Research 2005, 65:8984-8992.
101. Itoh T., Ando M., Tsukamasa Y., Akao Y. Expression of BMP-2 and Ets1 in BMP-2-stimulated mouse pre-osteoblast differentiation is regulated by microRNA-370. FEBS Letters 2012, 586:1693-1701.
102. Itoh T., Takeda S., Akao Y. MicroRNA-208 modulates BMP-2-stimulated mouse preosteoblast differentiation by directly targeting V-ets erythroblastosis virus E26 oncogene homolog 1. Journal of Biological Chemistry 2010, 285:27745-27752.
103. Jackers P., Szalai G., Moussa O., Watson D.K. Ets-dependent regulation of target gene expression during megakaryopoiesis. Journal of Biological Chemistry 2004, 279:52183-52190.
104. Jinnin M., Ihn H., Asano Y., Yamane K., Trojanowska M., Tamaki K. Upregulation of tenascin-C expression by IL-13 in human dermal fibroblasts via the phosphoinositide 3-kinase/Akt and the protein kinase C signaling pathways. The Journal of Investigative Dermatology 2006, 126:551-560.
105. Jinnin M., Ihn H., Mimura Y., Asano Y., Yamane K., Tamaki K. Matrix metalloproteinase-1 up-regulation by hepatocyte growth factor in human dermal fibroblasts via ERK signaling pathway involves Ets1 and Fli1. Nucleic Acids Research 2005, 33:3540-3549.
106. Jinnin M., Ihn H., Yamane K., Mimura Y., Asano Y., Tamaki K. Alpha2(I) collagen gene regulation by protein kinase C signaling in human dermal fibroblasts. Nucleic Acids Research 2005, 33:1337-1351.
107. Johnson T.R., Koul S., Kumar B., Khandrika L., Venezia S., Maroni P.D., et al. Loss of PDEF, a prostate-derived Ets factor is associated with aggressive phenotype of prostate cancer: Regulation of MMP 9 by PDEF. Molecular Cancer 2010, 9:148.
108. Jordan V.C. Tamoxifen: A most unlikely pioneering medicine. Nature Reviews. Drug Discovery 2003, 2:205-213.
109. Jung D., Choi Y., Uesugi M. Small organic molecules that modulate gene transcription. Drug Discovery Today 2006, 11:452-457.
110. Kanaya T., Hase K., Takahashi D., Fukuda S., Hoshino K., Sasaki I., et al. The Ets transcription factor Spi-B is essential for the differentiation of intestinal microfold cells. Nature Immunology 2012, 13:729-736.
111. Karnoub A.E., Dash A.B., Vo A.P., Sullivan A., Brooks M.W., Bell G.W., et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007, 449:557-563.
112. Kars M.D., Iseri O.D., Gunduz U. Drug resistant breast cancer cells overexpress ETS1 gene. Biomedicine & Pharmacotherapy 2010, 64:458-462.
113. Kawada H., Ito T., Pharr P.N., Spyropoulos D.D., Watson D.K., Ogawa M. Defective megakaryopoiesis and abnormal erythroid development in Fli-1 gene-targeted mice. International Journal of Hematology 2001, 73:463-468.
114. Kern H.B., Niemeyer B.F., Parrish J.K., Kerr C.A., Yaghi N.K., Prescott J.D., et al. Control of MicroRNA-21 expression in colorectal cancer cells by oncogenic epidermal growth factor/Ras signaling and Ets transcription factors. DNA and Cell Biology 2012, 31:1403-1411.
115. Kim H.L., Jeon K.H., Jun K.Y., Choi Y., Kim D.K., Na Y., et al. A-62176, a potent topoisomerase inhibitor, inhibits the expression of human epidermal growth factor receptor 2. Cancer Letters 2012, 325:72-79.
116. Kitange G., Shibata S., Tokunaga Y., Yagi N., Yasunaga A., Kishikawa M., et al. Ets-1 transcription factor-mediated urokinase-type plasminogen activator expression and invasion in glioma cells stimulated by serum and basic fibroblast growth factors. Laboratory Investigation 1999, 79:407-416.
117. Kohyama M., Ise W., Edelson B.T., Wilker P.R., Hildner K., Mejia C., et al. Role for Spi-C in the development of red pulp macrophages and splenic iron homeostasis. Nature 2009, 457:318-321.
118. Konstantinopoulos P.A., Papavassiliou A.G. Seeing the future of cancer-associated transcription factor drug targets. JAMA: The Journal of the American Medical Association 2011, 305:2349-2350.
119. Kosaka T., Miyajima A., Shirotake S., Kikuchi E., Hasegawa M., Mikami S., et al. Ets-1 and hypoxia inducible factor-1alpha inhibition by angiotensin II type-1 receptor blockade in hormone-refractory prostate cancer. The Prostate 2010, 70:162-169.
120. Kruse E.A., Loughran S.J., Baldwin T.M., Josefsson E.C., Ellis S., Watson D.K., et al. Dual requirement for the ETS transcription factors Fli-1 and Erg in hematopoietic stem cells and the megakaryocyte lineage. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:13814-13819.
121. Kubo M., Czuwara-Ladykowska J., Moussa O., Markiewicz M., Smith E., Silver R.M., et al. Persistent down-regulation of Fli1, a suppressor of collagen transcription, in fibrotic scleroderma skin. The American Journal of Pathology 2003, 163:571-581.
122. Kumar M.S., Narla A., Nonami A., Mullally A., Dimitrova N., Ball B., et al. Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q- syndrome. Blood 2011, 118:4666-4673.
123. Kumar-Sinha C., Tomlins S.A., Chinnaiyan A.M. Recurrent gene fusions in prostate cancer. Nature Reviews. Cancer 2008, 8:497-511.
124. Lacorazza H.D., Miyazaki Y., Di Cristofano A., Deblasio A., Hedvat C., Zhang J., et al. The ETS protein MEF plays a critical role in perforin gene expression and the development of natural killer and NK-T cells. Immunity 2002, 17:437-449.
125. Larsson E., Fredlund Fuchs P., Heldin J., Barkefors I., Bondjers C., Genove G., et al. Discovery of microvascular miRNAs using public gene expression data: miR-145 is expressed in pericytes and is a regulator of Fli1. Genome Medicine 2009, 1:108.
126. Lautenberger J.A., Papas T.S. Inversion of a chicken ets-1 proto-oncogene segment in avian leukemia virus E26. Journal of Virology 1993, 67:610-612.
127. Lavenburg K.R., Ivey J., Hsu T., Muise-Helmericks R.C. Coordinated functions of Akt/PKB and ETS1 in tubule formation. The FASEB Journal 2003, 17:2278-2280.
128. Lee G.M., Donaldson L.W., Pufall M.A., Kang H.S., Pot I., Graves B.J., et al. The structural and dynamic basis of Ets-1 DNA binding autoinhibition. Journal of Biological Chemistry 2005, 280:7088-7099.
129. Lee J., Kannagi M., Ferrante R.J., Kowall N.W., Ryu H. Activation of Ets-2 by oxidative stress induces Bcl-xL expression and accounts for glial survival in amyotrophic lateral sclerosis. The FASEB Journal 2009, 23:1739-1749.
130. Lelievre E., Lionneton F., Soncin F. Role of the ETS transcription factors in the control of endothelial-specific gene expression and in angiogenesis. Bulletin du Cancer 2001, 88:137-142.
131. Lelievre E., Lionneton F., Soncin F., Vandenbunder B. The Ets family contains transcriptional activators and repressors involved in angiogenesis. The International Journal of Biochemistry & Cell Biology 2001, 33:391-407.
132. Li R., Pei H., Watson D.K. Regulation of Ets function by protein-protein interactions. Oncogene 2000, 19:6514-6523.
133. Li R., Pei H., Watson D.K., Papas T.S. EAP1/Daxx interacts with ETS1 and represses transcriptional activation of ETS1 target genes. Oncogene 2000, 19:745-753.
134. Li F., Wallace J.A., Ostrowski M.C. ETS transcription factors in the tumor microenvironment. Open Cancer Journal 2010, 3:49-54.
135. Liao Y.L., Hu L.Y., Tsai K.W., Wu C.W., Chan W.C., Li S.C., et al. Transcriptional regulation of miR-196b by ETS2 in gastric cancer cells. Carcinogenesis 2012, 33:760-769.
136. Lin E.Y., Nguyen A.V., Russell R.G., Pollard J.W. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. The Journal of Experimental Medicine 2001, 193:727-740.
137. Lindemann R.K., Braig M., Ballschmieter P., Guise T.A., Nordheim A., Dittmer J. Protein kinase Calpha regulates Ets1 transcriptional activity in invasive breast cancer cells. International Journal of Oncology 2003, 22:799-805.
138. Lindemann R.K., Braig M., Hauser C.A., Nordheim A., Dittmer J. Ets2 and protein kinase Cepsilon are important regulators of parathyroid hormone-related protein expression in MCF-7 breast cancer cells. Biochemical Journal 2003, 372:787-797.
139. Liu F., Walmsley M., Rodaway A., Patient R. Fli1 acts at the top of the transcriptional network driving blood and endothelial development. Current Biology 2008, 18:1234-1240.
140. Loughran S.J., Kruse E.A., Hacking D.F., de Graaf C.A., Hyland C.D., Willson T.A., et al. The transcription factor Erg is essential for definitive hematopoiesis and the function of adult hematopoietic stem cells. Nature Immunology 2008, 9:810-819.
141. Manavathi B., Rayala S.K., Kumar R. Phosphorylation-dependent regulation of stability and transforming potential of ETS transcriptional factor ESE-1 by p21-activated kinase 1. Journal of Biological Chemistry 2007, 282:19820-19830.
142. Mardis E.R. ChIP-seq: Welcome to the new frontier. Nature Methods 2007, 4:613-614.
143. Maroni P., Bendinelli P., Matteucci E., Desiderio M.A. HGF induces CXCR4 and CXCL12-mediated tumor invasion through Ets1 and NF-kappaB. Carcinogenesis 2007, 28:267-279.
144. Massie C.E., Adryan B., Barbosa-Morais N.L., Lynch A.G., Tran M.G., Neal D.E., et al. New androgen receptor genomic targets show an interaction with the ETS1 transcription factor. EMBO Reports 2007, 8:871-878.
145. Masuya M., Moussa O., Abe T., Deguchi T., Higuchi T., Ebihara Y., et al. Dysregulation of granulocyte, erythrocyte, and NK cell lineages in Fli-1 gene-targeted mice. Blood 2005, 105:95-102.
146. Mathenia J., Reyes-Cortes E., Williams S., Molano I., Ruiz P., Watson D.K., et al. Impact of Fli-1 transcription factor on autoantibody and lupus nephritis in NZM2410 mice. Clinical and Experimental Immunology 2010, 162:362-371.
147. Mattot V., Vercamer C., Soncin F., Fafeur V., Vandenbunder B. Transcription factors of the Ets family and morphogenesis of the vascular tree. Journal de la Societe de Biologie 1999, 193:147-153.
148. Mavrothalassitis G., Ghysdael J. Proteins of the ETS family with transcriptional repressor activity. Oncogene 2000, 19:6524-6532.
149. McKinsey E.L., Parrish J.K., Irwin A.E., Niemeyer B.F., Kern H.B., Birks D.K., et al. A novel oncogenic mechanism in Ewing sarcoma involving IGF pathway targeting by EWS/Fli1-regulated microRNAs. Oncogene 2011, 30:4910-4920.
150. Miwa K., Nakashima H., Aoki M., Miyake T., Kawasaki T., Iwai M., et al. Inhibition of ets, an essential transcription factor for angiogenesis, to prevent the development of abdominal aortic aneurysm in a rat model. Gene Therapy 2005, 12:1109-1118.
151. Montes A.H., Valle-Garay E., Alvarez V., Pevida M., Garcia Perez E., Paz J., et al. A functional polymorphism in MMP1 could influence osteomyelitis development. Journal of Bone and Mineral Research 2010, 25:912-919.
152. Morris E.E., Amria M.Y., Kistner-Griffin E., Svenson J.L., Kamen D.L., Gilkeson G.S., et al. A GA microsatellite in the Fli1 promoter modulates gene expression and is associated with systemic lupus erythematosus patients without nephritis. Arthritis Research & Therapy 2010, 12:R212.
153. Mouly E., Chemin K., Nguyen H.V., Chopin M., Mesnard L., Leite-de-Moraes M., et al. The Ets-1 transcription factor controls the development and function of natural regulatory T cells. The Journal of Experimental Medicine 2010, 207:2113-2125.
154. Moussa O., LaRue A.C., Abangan R.S., Williams C.R., Zhang X.K., Masuya M., et al. Thrombocytopenia in mice lacking the carboxy-terminal regulatory domain of the Ets transcription factor Fli1. Molecular and Cellular Biology 2010, 30:5194-5206.
155. Moussa O., Turner D.P., Feldman R.J., Sementchenko V.I., McCarragher B.D., Desouki M.M., et al. PDEF is a negative regulator of colon cancer cell growth and migration. Journal of Cellular Biochemistry 2009, 108:1389-1398.
156. Myers E., Hill A.D., Kelly G., McDermott E.W., O'Higgins N.J., Buggy Y., et al. Associations and interactions between Ets-1 and Ets-2 and coregulatory proteins, SRC-1, AIB1, and NCoR in breast cancer. Clinical Cancer Research 2005, 11:2111-2122.
157. Nakerakanti S.S., Kapanadze B., Yamasaki M., Markiewicz M., Trojanowska M. Fli1 and Ets1 have distinct roles in connective tissue growth factor/CCN2 gene regulation and induction of the profibrotic gene program. Journal of Biological Chemistry 2006, 281:25259-25269.
158. Nam E.J., Yoon H., Kim S.W., Kim H., Kim Y.T., Kim J.H., et al. MicroRNA expression profiles in serous ovarian carcinoma. Clinical Cancer Research 2008, 14:2690-2695.
159. Ng A.Y., Waring P., Ristevski S., Wang C., Wilson T., Pritchard M., et al. Inactivation of the transcription factor Elf3 in mice results in dysmorphogenesis and altered differentiation of intestinal epithelium. Gastroenterology 2002, 122:1455-1466.
160. Nguyen H.V., Mouly E., Chemin K., Luinaud R., Despres R., Fermand J.P., et al. The Ets-1 transcription factor is required for Stat1-mediated T-bet expression and IgG2a class switching in mouse B cells. Blood 2012, 119:4174-4181.
161. Nicholson R.I., Gee J.M., Harper M.E. EGFR and cancer prognosis. European Journal of Cancer 2001, 37(Suppl. 4):S9-S15.
162. Niu Z., Goodyear S.M., Rao S., Wu X., Tobias J.W., Avarbock M.R., et al. MicroRNA-21 regulates the self-renewal of mouse spermatogonial stem cells. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:12740-12745.
163. Nowling T.K., Fulton J.D., Chike-Harris K., Gilkeson G.S. Ets factors and a newly identified polymorphism regulate Fli1 promoter activity in lymphocytes. Molecular Immunology 2008, 45:1-12.
164. O'Leary D.A., Noakes P.G., Lavidis N.A., Kola I., Hertzog P.J., Ristevski S. Targeting of the ETS factor GABPalpha disrupts neuromuscular junction synaptic function. Molecular and Cellular Biology 2007, 27:3470-3480.
165. Orimo A., Weinberg R.A. Stromal fibroblasts in cancer: A novel tumor-promoting cell type. Cell Cycle 2006, 5:1597-1601.
166. Pan H.F., Leng R.X., Tao J.H., Li X.P., Ye D.Q. Ets-1: A new player in the pathogenesis of systemic lupus erythematosus?. Lupus 2011, 20:227-230.
167. Pang L., Xue H.H., Szalai G., Wang X., Wang Y., Watson D.K., et al. Maturation stage-specific regulation of megakaryopoiesis by pointed-domain Ets proteins. Blood 2006, 108:2198-2206.
168. Papadaki C., Alexiou M., Cecena G., Verykokakis M., Bilitou A., Cross J.C., et al. Transcriptional repressor erf determines extraembryonic ectoderm differentiation. Molecular and Cellular Biology 2007, 27:5201-5213.
169. Park C., Hennig G.W., Sanders K.M., Cho J.H., Hatton W.J., Redelman D., et al. Serum response factor-dependent MicroRNAs regulate gastrointestinal smooth muscle cell phenotypes. Gastroenterology 2011, 141:164-175.
170. Park K.S., Korfhagen T.R., Bruno M.D., Kitzmiller J.A., Wan H., Wert S.E., et al. SPDEF regulates goblet cell hyperplasia in the airway epithelium. The Journal of Clinical Investigation 2007, 117:978-988.
171. Pei H., Yordy J.S., Leng Q., Zhao Q., Watson D.K., Li R. EAPII interacts with ETS1 and modulates its transcriptional function. Oncogene 2003, 22:2699-2709.
172. Pimanda J.E., Ottersbach K., Knezevic K., Kinston S., Chan W.Y., Wilson N.K., et al. Gata2, Fli1, and Scl form a recursively wired gene-regulatory circuit during early hematopoietic development. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:17692-17697.
173. Pourtier-Manzanedo A., Vercamer C., Van Belle E., Mattot V., Mouquet F., Vandenbunder B. Expression of an Ets-1 dominant-negative mutant perturbs normal and tumor angiogenesis in a mouse ear model. Oncogene 2003, 22:1795-1806.
174. Rahim S., Beauchamp E.M., Kong Y., Brown M.L., Toretsky J.A., Uren A. YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion. PLoS One 2011, 6:e19343.
175. Rajewsky N. microRNA target predictions in animals. Nature Genetics 2006, 38(Suppl.):S8-S13.
176. Raslova H., Komura E., Le Couedic J.P., Larbret F., Debili N., Feunteun J., et al. FLI1 monoallelic expression combined with its hemizygous loss underlies Paris-Trousseau/Jacobsen thrombopenia. The Journal of Clinical Investigation 2004, 114:77-84.
177. Riggi N., Suva M.L., De Vito C., Provero P., Stehle J.C., Baumer K., et al. EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cells. Genes & Development 2010, 24:916-932.
178. Romania P., Lulli V., Pelosi E., Biffoni M., Peschle C., Marziali G. MicroRNA 155 modulates megakaryopoiesis at progenitor and precursor level by targeting Ets-1 and Meis1 transcription factors. British Journal of Haematology 2008, 143:570-580.
179. Sahin A., Velten M., Pietsch T., Knuefermann P., Okuducu A.F., Hahne J.C., et al. Inactivation of Ets 1 transcription factor by a specific decoy strategy reduces rat C6 glioma cell proliferation and mmp-9 expression. International Journal of Molecular Medicine 2005, 15:771-776.
180. Salh B., Marotta A., Wagey R., Sayed M., Pelech S. Dysregulation of phosphatidylinositol 3-kinase and downstream effectors in human breast cancer. International Journal of Cancer 2002, 98:148-154.
181. Schaefer J.S., Sabherwal Y., Shi H.Y., Sriraman V., Richards J., Minella A., et al. Transcriptional regulation of p21/CIP1 cell cycle inhibitor by PDEF controls cell proliferation and mammary tumor progression. Journal of Biological Chemistry 2010, 285:11258-11269.
182. Schmidt D., Wilson M.D., Spyrou C., Brown G.D., Hadfield J., Odom D.T. ChIP-seq: Using high-throughput sequencing to discover protein-DNA interactions. Methods 2009, 48:240-248.
183. Schotte R., Nagasawa M., Weijer K., Spits H., Blom B. The ETS transcription factor Spi-B is required for human plasmacytoid dendritic cell development. The Journal of Experimental Medicine 2004, 200:1503-1509.
184. Sementchenko V.I., Schweinfest C.W., Papas T.S., Watson D.K. ETS2 function is required to maintain the transformed state of human prostate cancer cells. Oncogene 1998, 17:2883-2888.
185. Sementchenko V.I., Watson D.K. Ets target genes: Past, present and future. Oncogene 2000, 19:6533-6548.
186. Seth A., Watson D.K. ETS transcription factors and their emerging roles in human cancer. European Journal of Cancer 2005, 41:2462-2478.
187. Shah R.B., Chinnaiyan A.M. The discovery of common recurrent transmembrane protease serine 2 (TMPRSS2)-erythroblastosis virus E26 transforming sequence (ETS) gene fusions in prostate cancer: Significance and clinical implications. Advances in Anatomic Pathology 2009, 16:145-153.
188. Shah S., Small E. Emerging biological observations in prostate cancer. Expert Review of Anticancer Therapy 2010, 10:89-101.
189. Shilo S., Roy S., Khanna S., Sen C.K. MicroRNA in cutaneous wound healing: A new paradigm. DNA and Cell Biology 2007, 26:227-237.
190. Shimogawa H., Kwon Y., Mao Q., Kawazoe Y., Choi Y., Asada S., et al. A wrench-shaped synthetic molecule that modulates a transcription factor-coactivator interaction. Journal of the American Chemical Society 2004, 126:3461-3471.
191. Shirasaki F., Makhluf H.A., LeRoy C., Watson D.K., Trojanowska M. Ets transcription factors cooperate with Sp1 to activate the human tenascin-C promoter. Oncogene 1999, 18:7755-7764.
192. Sica A., Larghi P., Mancino A., Rubino L., Porta C., Totaro M.G., et al. Macrophage polarization in tumour progression. Seminars in Cancer Biology 2008, 18:349-355.
193. Sieweke M.H., Tekotte H., Frampton J., Graf T. MafB is an interaction partner and repressor of Ets-1 that inhibits erythroid differentiation. Cell 1996, 85:49-69.
194. Soller M.J., Isaksson M., Elfving P., Soller W., Lundgren R., Panagopoulos I. Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer. Genes, Chromosomes & Cancer 2006, 45:717-719.
195. Span P.N., Manders P., Heuvel J.J., Thomas C.M., Bosch R.R., Beex L.V., et al. Expression of the transcription factor Ets-1 is an independent prognostic marker for relapse-free survival in breast cancer. Oncogene 2002, 21:8506-8509.
196. Spyropoulos D.D., Pharr P.N., Lavenburg K.R., Jackers P., Papas T.S., Ogawa M., et al. Hemorrhage, impaired hematopoiesis, and lethality in mouse embryos carrying a targeted disruption of the Fli1 transcription factor. Molecular and Cellular Biology 2000, 20:5643-5652.
197. Starck J., Weiss-Gayet M., Gonnet C., Guyot B., Vicat J.M., Morle F. Inducible Fli-1 gene deletion in adult mice modifies several myeloid lineage commitment decisions and accelerates proliferation arrest and terminal erythrocytic differentiation. Blood 2010, 116:4795-4805.
198. Stegmaier K., Wong J.S., Ross K.N., Chow K.T., Peck D., Wright R.D., et al. Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma. PLoS Medicine 2007, 4:e122.
199. Szalai G., LaRue A.C., Watson D.K. Molecular mechanisms of megakaryopoiesis. Cellular and Molecular Life Sciences 2006, 63:2460-2476.
200. Takai N., Miyazaki T., Nishida M., Nasu K., Miyakawa I. c-Ets1 is a promising marker in epithelial ovarian cancer. International Journal of Molecular Medicine 2002, 9:287-292.
201. Titeux M., Pendaries V., Tonasso L., Decha A., Bodemer C., Hovnanian A. A frequent functional SNP in the MMP1 promoter is associated with higher disease severity in recessive dystrophic epidermolysis bullosa. Human Mutation 2008, 29:267-276.
202. Tomlins S.A., Laxman B., Dhanasekaran S.M., Helgeson B.E., Cao X., Morris D.S., et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 2007, 448:595-599.
203. Tomlins S.A., Rhodes D.R., Perner S., Dhanasekaran S.M., Mehra R., Sun X.W., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005, 310:644-648.
204. Tootle T.L., Rebay I. Post-translational modifications influence transcription factor activity: A view from the ETS superfamily. BioEssays 2005, 27:285-298.
205. Trojanowska M. Ets factors and regulation of the extracellular matrix. Oncogene 2000, 19:6464-6471.
206. Truong A.H., Ben-David Y. The role of Fli-1 in normal cell function and malignant transformation. Oncogene 2000, 19:6482-6489.
207. Tsui K.H., Chung L.C., Feng T.H., Chang P.L., Juang H.H. Upregulation of prostate-derived Ets factor by luteolin causes inhibition of cell proliferation and cell invasion in prostate carcinoma cells. International Journal of Cancer 2012, 130:2812-2823.
208. Tugores A., Le J., Sorokina I., Snijders A.J., Duyao M., Reddy P.S., et al. The epithelium-specific ETS protein EHF/ESE-3 is a context-dependent transcriptional repressor downstream of MAPK signaling cascades. Journal of Biological Chemistry 2001, 276:20397-20406.
209. Turner D.P., Findlay V.J., Kirven A.D., Moussa O., Watson D.K. Global gene expression analysis identifies PDEF transcriptional networks regulating cell migration during cancer progression. Molecular Biology of the Cell 2008, 19:3745-3757.
210. Turner D.P., Findlay V.J., Moussa O., Semenchenko V.I., Watson P.M., LaRue A.C., et al. Mechanisms and functional consequences of PDEF protein expression loss during prostate cancer progression. The Prostate 2011, 71:1723-1735.
211. Turner D.P., Findlay V.J., Moussa O., Watson D.K. Defining ETS transcription regulatory networks and their contribution to breast cancer progression. Journal of Cellular Biochemistry 2007, 102:549-559.
212. Turner D.P., Moussa O., Sauane M., Fisher P.B., Watson D.K. Prostate-derived ETS factor is a mediator of metastatic potential through the inhibition of migration and invasion in breast cancer. Cancer Research 2007, 67:1618-1625.
213. Turner D.P., Watson D.K. ETS transcription factors: Oncogenes and tumor suppressor genes as therapeutic targets for prostate cancer. Expert Review of Anticancer Therapy 2008, 8:33-42.
214. Verger A., Duterque-Coquillaud M. When Ets transcription factors meet their partners. BioEssays 2002, 24:362-370.
215. Visel A., Blow M.J., Li Z., Zhang T., Akiyama J.A., Holt A., et al. ChIP-seq accurately predicts tissue-specific activity of enhancers. Nature 2009, 457:854-858.
216. Vitari A.C., Leong K.G., Newton K., Yee C., O'Rourke K., Liu J., et al. COP1 is a tumour suppressor that causes degradation of ETS transcription factors. Nature (London) 2011, 474:403-406.
217. Wang Y., Fan P.S., Kahaleh B. Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis and Rheumatism 2006, 54:2271-2279.
218. Wang Y., Feng L., Said M., Balderman S., Fayazi Z., Liu Y., et al. Analysis of the 2.0 A crystal structure of the protein-DNA complex of the human PDEF Ets domain bound to the prostate specific antigen regulatory site. Biochemistry 2005, 44:7095-7106.
219. Wang D., John S.A., Clements J.L., Percy D.H., Barton K.P., Garrett-Sinha L.A. Ets-1 deficiency leads to altered B cell differentiation, hyperresponsiveness to TLR9 and autoimmune disease. International Immunology 2005, 17:1179-1191.
220. Wang C., Li Q. Identification of differentially expressed microRNAs during the development of Chinese murine mammary gland. Journal of Genetics and Genomics 2007, 34:966-973.
221. Wang Y., Stricker H.M., Gou D., Liu L. MicroRNA: Past and present. Frontiers in Bioscience 2007, 12:2316-2329.
222. Wang L.C., Swat W., Fujiwara Y., Davidson L., Visvader J., Kuo F., et al. The TEL/ETV6 gene is required specifically for hematopoiesis in the bone marrow. Genes & Development 1998, 12:2392-2402.
223. Wang C., Zhang H., Chen Y., Shi F., Chen B. Gambogic acid-loaded magnetic Fe(3)O(4) nanoparticles inhibit Panc-1 pancreatic cancer cell proliferation and migration by inactivating transcription factor ETS1. International Journal of Nanomedicine 2012, 7:781-787.
224. Watabe T., Yoshida K., Shindoh M., Kaya M., Fujikawa K., Sato H., et al. The Ets-1 and Ets-2 transcription factors activate the promoters for invasion-associated urokinase and collagenase genes in response to epidermal growth factor. International Journal of Cancer 1998, 77:128-137.
225. Watson D.K., Ascione R., Papas T.S. Molecular analysis of the ets genes and their products. Critical Reviews in Oncogenesis 1990, 1:409-436.
226. Watson D.K., Smyth F.E., Thompson D.M., Cheng J.Q., Testa J.R., Papas T.S., et al. The ERGB/Fli-1 gene: Isolation and characterization of a new member of the family of human ETS transcription factors. Cell Growth & Differentiation 1992, 3:705-713.
227. Watson D.K., Turner D.P., Scheiber M.N., Findlay V.J., Watson P.M. ETS transcription factor expression and conversion during prostate and breast cancer progression. Open Cancer Journal 2010, 3:24-39.
228. Wei G.H., Badis G., Berger M.F., Kivioja T., Palin K., Enge M., et al. Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo. EMBO Journal 2010, 29:2147-2160.
229. Wei G., Srinivasan R., Cantemir-Stone C.Z., Sharma S.M., Santhanam R., Weinstein M., et al. Ets1 and Ets2 are required for endothelial cell survival during embryonic angiogenesis. Blood 2009, 114:1123-1130.
230. Wernert N., Stanjek A., Kiriakidis S., Hugel A., Jha H.C., Mazitschek R., et al. Inhibition of angiogenesis in vivo by ets-1 antisense oligonucleotides-inhibition of Ets-1 transcription factor expression by the antibiotic fumagillin. Angewandte Chemie International Edition 1999, 38:3228-3231. (in English).
231. Westermarck J., Seth A., Kahari V.M. Differential regulation of interstitial collagenase (MMP-1) gene expression by ETS transcription factors. Oncogene 1997, 14:2651-2660.
232. Wiemer E.A. The role of microRNAs in cancer: No small matter. European Journal of Cancer 2007, 43:1529-1544.
233. Wood L.D., Irvin B.J., Nucifora G., Luce K.S., Hiebert S.W. Small ubiquitin-like modifier conjugation regulates nuclear export of TEL, a putative tumor suppressor. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:3257-3262.
234. Wu Y.H., Hu T.F., Chen Y.C., Tsai Y.N., Tsai Y.H., Cheng C.C., et al. The manipulation of miRNA-gene regulatory networks by KSHV induces endothelial cell motility. Blood 2011, 118:2896-2905.
235. Xu C., Liu S., Fu H., Li S., Tie Y., Zhu J., et al. MicroRNA-193b regulates proliferation, migration and invasion in human hepatocellular carcinoma cells. European Journal of Cancer 2010, 46:2828-2836.
236. Xu D., Wilson T.J., Chan D., De Luca E., Zhou J., Hertzog P.J., et al. Ets1 is required for p53 transcriptional activity in UV-induced apoptosis in embryonic stem cells. EMBO Journal 2002, 21:4081-4093.
237. Yamada N., Tamai Y., Miyamoto H., Nozaki M. Cloning and expression of the mouse Pse gene encoding a novel Ets family member. Gene 2000, 241:267-274.
238. Yamamoto H., Flannery M.L., Kupriyanov S., Pearce J., McKercher S.R., Henkel G.W., et al. Defective trophoblast function in mice with a targeted mutation of Ets2. Genes & Development 1998, 12:1315-1326.
239. Yang S.H., Sharrocks A.D. SUMO promotes HDAC-mediated transcriptional repression. Molecular Cell 2004, 13:611-617.
240. Yang W., Shen N., Ye D.Q., Liu Q., Zhang Y., Qian X.X., et al. Genome-wide association study in Asian populations identifies variants in ETS1 and WDFY4 associated with systemic lupus erythematosus. PLoS Genetics 2010, 6:e1000841.
241. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nature Reviews. Molecular Cell Biology 2001, 2:127-137.
242. Ye M., Coldren C., Liang X., Mattina T., Goldmuntz E., Benson D.W., et al. Deletion of ETS-1, a gene in the Jacobsen syndrome critical region, causes ventricular septal defects and abnormal ventricular morphology in mice. Human Molecular Genetics 2010, 19:648-656.
243. Yordy J.S., Li R., Sementchenko V.I., Pei H., Muise-Helmericks R.C., Watson D.K. SP100 expression modulates ETS1 transcriptional activity and inhibits cell invasion. Oncogene 2004, 23:6654-6665.
244. Yordy J.S., Muise-Helmericks R.C. Signal transduction and the Ets family of transcription factors. Oncogene 2000, 19:6503-6513.
245. Yu S., Zhao D.M., Jothi R., Xue H.H. Critical requirement of GABPalpha for normal T cell development. Journal of Biological Chemistry 2010, 285:10179-10188.
246. Zabuawala T., Taffany D.A., Sharma S.M., Merchant A., Adair B., Srinivasan R., et al. An ets2-driven transcriptional program in tumor-associated macrophages promotes tumor metastasis. Cancer Research 2010, 70:1323-1333.
247. Zhang L., Eddy A., Teng Y.-T., Fritzler M., Kluppel M., Melet F., et al. An immunological renal disease in transgenic mice that overexpress Fli-1, a member of the ets family of transcription factor genes. Molecular and Cellular Biology 1995, 15:6961-6970.
248. Zhang X.K., Gallant S., Molano I., Moussa O.M., Ruiz P., Spyropoulos D.D., et al. Decreased expression of the Ets family transcription factor Fli-1 markedly prolongs survival and significantly reduces renal disease in MRL/lpr mice. Journal of Immunology 2004, 173:6481-6489.
249. Zhang J., Guo H., Zhang H., Wang H., Qian G., Fan X., et al. Putative tumor suppressor miR-145 inhibits colon cancer cell growth by targeting oncogene Friend leukemia virus integration 1 gene. Cancer 2011, 117:86-95.
250. Zhang X.K., Moussa O., LaRue A., Bradshaw S., Molano I., Spyropoulos D.D., et al. The transcription factor Fli-1 modulates marginal zone and follicular B cell development in mice. Journal of Immunology 2008, 181:1644-1654.
251. Zhang Z., Verheyden J.M., Hassell J.A., Sun X. FGF-regulated Etv genes are essential for repressing Shh expression in mouse limb buds. Developmental Cell 2009, 16:607-613.
252. Zhang Y., Yan L.X., Wu Q.N., Du Z.M., Chen J., Liao D.Z., et al. miR-125b is methylated and functions as a tumor suppressor by regulating the ETS1 proto-oncogene in human invasive breast cancer. Cancer Research 2011, 71:3552-3562.
253. Zhou J., Chehab R., Tkalcevic J., Naylor M.J., Harris J., Wilson T.J., et al. Elf5 is essential for early embryogenesis and mammary gland development during pregnancy and lactation. EMBO Journal 2005, 24:635-644.
254. Zhou J., Ng A.Y., Tymms M.J., Jermiin L.S., Seth A.K., Thomas R.S., et al. A novel transcription factor, ELF5, belongs to the ELF subfamily of ETS genes and maps to human chromosome 11p13-15, a region subject to LOH and rearrangement in human carcinoma cell lines. Oncogene 1998, 17:2719-2732.
255. Zhu N., Zhang D., Chen S., Liu X., Lin L., Huang X., et al. Endothelial enriched microRNAs regulate angiotensin II-induced endothelial inflammation and migration. Atherosclerosis 2011, 215:286-293.
256. Zou Z., Anisowicz A., Hendrix M.J., Thor A., Neveu M., Sheng S., et al. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science 1994, 263:526-529.
257. Zucman J., Delattre O., Desmaze C., Plougastel B., Joubert I., Melot T., et al. Cloning and characterization of the Ewing's sarcoma and peripheral neuroepithelioma t(11; 22) translocation breakpoints. Genes, Chromosomes & Cancer 1992, 5:271-277.